Ipsen Biopharmaceuticals, Inc.
1 Main Street
Unit 700
Cambridge
MA
02142
United States
Tel: 617-679-8500
Website: https://www.ipsenus.com/
Email: talentacquisition@ipsen.com
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
595 articles about Ipsen Biopharmaceuticals, Inc.
-
Ipsen: Half-Year Statement of Ipsen's Liquidity Contract
1/15/2008
-
Second Symposium on Biological Complexity: 'Genes, Circuits and Behavior' Jointly Organized by the Salk Institute for Biological Studies, Nature and La Fondation Ipsen
1/11/2008
-
Ipsen and the Salk Institute for Biological Studies Enter into Strategic Research Agreement
1/11/2008
-
Ipsen.: Disclosure of Trading in Own Shares
1/4/2008
-
Two Years after Its IPO, Ipsen Enters The SBF 120 Index
1/3/2008
-
Ipsen Announces Its Corporate Agenda for 2008
12/20/2007
-
Medicis and Ipsen Announce Submission of Reloxin in Aesthetics to the FDA
12/6/2007
-
Ipsen Submits a Biologics License Application (BLA) in Cervical Dystonia to the FDA for Dysport®
12/6/2007
-
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport® in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
12/6/2007
-
Ipsen and Medicis Announce Submission of Reloxin® in Aesthetics to the FDA
12/6/2007
-
New Collaboration between Ipsen and Erasmus MC in Endocrinology
12/4/2007
-
Celera Genomics Group-an Applera Corp. Business and Ipsen Enter Research Collaboration to Develop Pharmacogenomic Tests
11/21/2007
-
Ipsen's First Nine Months of 2007 Sales
11/6/2007
-
Ipsen and Debiopharm S.A. Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) in Europe and Certain Other Territories
10/31/2007
-
Ipsen: Disclosure of Trading in Own Shares(1) in September 2007
10/5/2007
-
Ipsen Could Receive 125 Million if Novartis Corporation (Jobs) Exercises BA058 Option
9/17/2007
-
bioMerieux SA (Jobs) and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment
9/17/2007
-
Tercica, Inc. and Ipsen: Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
8/31/2007
-
Ipsen's First Half 2007 Results and Financial Objectives for the Full Year 2007
8/29/2007
-
Ipsen Transfers Ginkor Fort(R) Marketing Authorizations To GTF For France, Monaco and Andorra
8/23/2007